Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Birth tissues could be goldmine for stem cells, study finds

NCT ID NCT07169838

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether stem cells can be made from tissues that are normally thrown away after childbirth, like the umbilical cord and placenta. Researchers collected 160 samples from healthy mothers and tested how many stem cells they could get, how clean the samples were, and how much it cost. The goal was to find the best and cheapest way to produce these cells for future medical use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help make stem cell production from birth tissues cheaper and more efficient, potentially improving access to regenerative medicine.
What could go wrong
This was a small, completed lab study, not a treatment trial. The results may not translate to real-world medical use or benefit patients directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

160 people

The number who actually took part.

Started

Jan 2023

Finished

Aug 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of 160 healthy women with uncomplicated singleton pregnancies who delivered at term (≥37 weeks) at Kayseri City Hospital and Eskişehir Osmangazi University Hospital in Türkiye. Participants were aged between 18 and 45 years. Perinatal tissues, including amniotic fluid, amniotic membrane, umbilical cord, and placenta, were collected immediately after delivery as medical waste, with no additional intervention applied. All participants provided written informed consent.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants only * Age between 18 and 45 years * Singleton, uncomplicated term pregnancies (≥37 weeks of gestation) * Delivery by either elective cesarean section or spontaneous vaginal birth * Written informed consent obtained prior to sample collection Exclusion Criteria: * Presence of maternal infection at the time of delivery * Known fetal malformations or chromosomal abnormalities * Placental abnormalities (e.g., previa, abruption) * Preterm labor (\<37 weeks) * Any maternal comorbidity that may compromise tissue quality (e.g., uncontrolled diabetes, hypertension, autoimmune disease) * Inability or unwillingness to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perinatal medical waste are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kayseri City Hospital

    Kayseri, Kayseri, 38130, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.